Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Adverse effects
[105] RCT	5926 people with vascular disease who were intolerant to ACE inhibitors	Withdrawal for any cause 1090/2954 (37%) with telmisartan 1143/2972 (39%) with placebo	P = 0.22		Not significant
[105] RCT	5926 people with vascular disease who were intolerant to ACE inhibitors	Hypotensive symptoms 29/2954 (1.0%) with telmisartan 16/2972 (0.5%) with placebo	P = 0.05		Not significant
[105] RCT	5926 people with vascular disease who were intolerant to ACE inhibitors	Doubling of serum creatinine 60/2954 (2.0%) with telmisartan 42/2972 (1.4%) with placebo	Significance not assessed
[105] RCT	5926 people with vascular disease who were intolerant to ACE inhibitors	Hyperkalaemia (potassium >5.5 mmol/L) 111/2954 (4%) with telmisartan 49/2972 (2%) with placebo	Significance not assessed
[106] RCT	20,332 people with previous stroke and risk factors for vascular disease	Withdrawal because of adverse effects 1450/10,146 (14%) with telmisartan 1127/10,186 (11%) with placebo	P <0.001	Effect size not calculated	placebo
[106] RCT	20,332 people with previous stroke and risk factors for vascular disease	Withdrawal because of hypotension 393/10,146 (4%) with telmisartan 186/10,186 (2%) with placebo	P <0.001	Effect size not calculated	placebo